Coronavirus Stimulus Bill, Remdesivir’s Orphan Status, Teva’s Copaxone Suit

Citeline Podcasts

English - March 27, 2020 14:16 - 22 minutes - 20.9 MB - ★★★★★ - 24 ratings
Business News Business News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: How The Coronavirus Is Impacting The European OTC Industry

Next Episode: Scrip Podcast-Ep4 March 2020:Coronavirus:Remdesivir and Pipeline Hopes–Long-Term Impact On Biopharma

Pink Sheet editor and reports discuss pharma’s wins in the latest coronavirus stimulus bill, explain Gilead’s decision to pull the remdesivir orphan designation, and consider Teva’s suit to force Copaxone’s transition to regulation as a biologic.